Business Context and Reporting Period
X4 Pharmaceuticals, Inc. (XFOR), a Delaware corporation and emerging growth company, filed this Form 8-K on March 17, 2020, reporting events occurring on March 13, 2020. The filing details the entry into a material definitive agreement regarding a significant amendment to its existing loan facility.
Key Financial Metrics and Debt Structure
The filing focuses on debt financing rather than operational financial performance metrics such as revenue or profit, which are not provided in this document.
- Total Maximum Borrowing Capacity: Up to $50.0 million.
- Tranche 1 (Immediate): $25.0 million total term loan, comprising $20.0 million previously outstanding and a new $5.0 million advance drawn on March 13, 2020.
- Tranche 2 (Milestone-based): Up to $7.5 million available through June 30, 2021.
- Tranche 3 (Milestone-based): Up to $7.5 million available through June 30, 2022.
- Tranche 4 (Discretionary): Up to $10.0 million available through December 31, 2022, subject to the Lender's investment committee discretion.
- Interest Rate: Variable rate equal to the greater of (i) 3.75% plus the prime rate or (ii) 8.75%. In the event of default, the rate increases by 4.0%.
- Repayment Terms: Monthly interest-only payments through January 1, 2022. Principal and interest payments commence February 1, 2022, with a maturity date of July 1, 2023.
- Additional Fees: A $795,000 fee payable by November 1, 2021, or upon full repayment. A 4.0% fee on aggregate principal drawn (up to $2.0 million) payable at maturity or full repayment.
- Collateral: Substantially all personal property and assets, excluding intellectual property (though including rights to proceeds from IP).
Material Changes Versus Prior Period
The primary material change is the amendment of the Amended and Restated Loan and Security Agreement dated June 27, 2019. This amendment increased the total available borrowing capacity and added a $5.0 million immediate cash advance. The filing does not provide comparative financial data (e.g., revenue or cash flow) for prior periods.
Guidance, Risks, and Covenants
Covenants and Liquidity Requirements:
- Cash Maintenance: Once outstanding principal exceeds $25.0 million, the Borrower must maintain cash in a secured account equal to the greater of $30.0 million or 6x the Rolling Monthly Liquidity (RML) metric. This requirement may be reduced to the greater of $20.0 million or 3x RML upon achieving certain milestones.
- Restrictions: The agreement restricts incurring additional indebtedness, paying dividends, encumbering intellectual property, and engaging in mergers or acquisitions.
Risks and Contingencies:
- Events of Default: Obligations are subject to acceleration upon payment default, insolvency, or a material adverse change in the business.
- Prepayment Penalties: Prepayment is allowed but subject to premiums ranging from 0.5% to 2.0% depending on the timing of repayment.
- Equity Participation: Hercules Capital has the right to participate in future equity offerings for financing purposes up to $3.0 million in the aggregate ($1.0 million already exercised).
Investor Verification Checklist
- Verify the current cash balance to ensure compliance with the $30.0 million (or 6x RML) liquidity covenant now that the loan balance exceeds $25.0 million.
- Confirm the specific performance milestones required to unlock Tranches 2 and 3 and to reduce liquidity covenant requirements.
- Review the definition of "Rolling Monthly Liquidity" (RML) to assess the volatility of the cash maintenance requirement.
- Assess the impact of the 4.0% fee on total principal drawn and the $795,000 fee on the company's future cash flow projections.
- Monitor the company's ability to meet the July 1, 2023, maturity date given the interest-only period ending in early 2022.